Tacrolimus pharmacokinetic and pharmacogenomic differences between adults and pediatric solid organ transplant recipients

Pharmaceutics

Volumn 2, Issue 3, 2010, Pages 291-299

  Marfo, Kwaku ^a   Altshuler, Jerry ^b   Lu, Amy ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

FK 506; Pediatric transplant; Pharmacogenomics; Pharmacokinetics; Tacrolimus

Indexed keywords

ALBUMIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; OROSOMUCOID; TACROLIMUS;

ADULT; AGE DISTRIBUTION; CHILD; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; PHARMACOGENOMICS; PHARMACOKINETICS; PROTEIN EXPRESSION; REVIEW;

EID: 79952172595     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics2030291     Document Type: Review

References (51)

1. Goto, T.; Kino, T.; Hatanaka, H.; Nishiyama, M.; Okuhara, M.; Kohsaka, M.; Aoki, H.; Imanaka H. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces Tsukubaensis. Transplant. Proc. 1987, 19, 4-8.
2. UNOS Market Share Report. Immunosuppression and practice trend. 2002, chapter 4. Available at http://wwwunos.org/ (accessed on July 16, 2010).
3. Knoll, G.A.; Bell, R.C. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. Br. Med. J. 1999, 318, 1104-1107.
4. Pirsch, J.D.; Miller, J.; Deierhoi, M.H.; Vincenti, F.; Filo, R.S. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997, 63, 977-983.
5. Mayer, A.D; Dmitrewski, J.; Squifflet, J.-P.; Besse, T.; Grabensee, B.; Klein, B.; Eigler, F.W.; Heemann, U.; Pichlmayr, R.; Behrend, M.; Vanrenterghem, Y.; Donck, J.; van Hooff, J.; Christiaans, M.; Morales, J.M.; Andres, A.; Johnson, R.W.G.; Short, C.; Buchholz, B.; Rehmert, N.; Land, W.; Schleibner, S.; Forsythe, J.L.R.; Talbot, D.; Neumayer, H.-H.; Hauser, I.; Ericzon, B.-G.; Brattström, C.; Claesson, K.; Mühlbacher, F.; Pohanka, E. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997, 64, 436-443.
6. Peters, D.H.; Fitton, A.; Plosker, G.L.; Faulds, D. Tacrolimus. A review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 1993, 46, 74-749.
7. Plosker, G.L.; Foster, R.H. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000, 59, 323-389.
8. Brazelton, T.R.; Morris, R.E. Molecular mechanism of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (Rapamycin), mycophenolate mofetil and leflunomide. Curr. Opin. Immunol. 1996, 8, 710-720
9. Thomsan, A.W.; Bonham, C.A.; Zeevi, A. A mode of action of tacrolimus (FK-506): Molecular and cellular and cellular mechanisms. Ther. Drug Monit. 1995, 17, 584-591.
10. Danovitch, G.M. Immunosuppresive Medications and Protocols for Kidney Transplantation. In Handbook of Kidney Transplantation; Danovitch, G.M., Ed.; Lippincott Williams & Wilkins: New York, NY, USA, 2005; pp. 72-90.
11. Quan, D.J.; Winter, M.E. Immunosuppressants: Cyclosporine, tacrolimus and sirolimus. In Basic Clinical Pharmacokinetics, Winter; Lippincott Williams and Wilkins: New York, NY, USA, 2004; p. 241.
12. Besunder, J.B.; Reed, M.D.; Blumer, J.L. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I). Clin. Pharmacokinet. 1988, 14, 189-216.
13. Kelly, P.A.; Burckart, G.J.; Venkatatamanan, R. Tacrolimus: A new Immunosuppresive agent. Am. J. Health Syst. Pharm. 1995, 52, 1521-1535.
14. Astellas Pharma US, Inc. Prograf (tacrolimus) Prescribing Information; Astellas Pharma US, Inc.: Deerfield, IL, USA, 2009.
15. Rane, A. Drug Disposition and Action in Infants and Children. In Pediatric Pharmacology: Therapeutic Principles in Practice, 2nd ed.; Yaffe, S.J., Aranda, J.V., Eds.; WB Saunders: Philadelphia, PA, USA, 1992; pp. 10-21.
16. Dumont, R.C.; Rudolph, C.D. Development of gastrointestinal motility in the infant and child. Gastrointest. Clin. North Am. 1994, 23, 655-671.
17. Friis-Hansen, B. Body composition during groth in vivo measurements and biochemical data correlated to differential anatomical growth. Pediatrics 1971, 47, 264-274.
18. Miyoshi, K.; Saijo, K.; Kotani, Y.; Kashiwagi, T.; Kawai, H. Characteristics of fetal human albumin in isomerization equilibrium. Tokushima J. Exp. Med. 1966, 13, 121-132.
19. Notarianni, L.J. Plasma protein binding of drugs in pregnancy and neonates. Clin. Pharmacokinet. 1990, 18, 20-36.
20. Johnson, T.N.; Rostami-Hodjegan, A.; Tucker, G.T. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 2006, 45, 931-956.
21. Tanaka, E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J. Clin. Pharm. Ther. 1998, 23, 247-255.
22. May, D.G.; Porter, J.; Wilkinson, G.R.; Branch, R.A. Frequency distribution of dapsone-N-hydroxylase, a putative probe of P4503A4 activity, in a white population. Clin. Pharmacol. Ther.1994, 55, 492-500.
23. Filler, G.; Grygas, R.; Mai, I.; Stolpe, H.J.; Greiner, C.; Bauer, S.; Ehrich, J.H. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol. Dial. Transplant 1997, 12, 1668-1671.
24. Astellas Pharma US Inc. Prograf prescribing information (US) [online]. Available from at http://www.astellas.us/docs/prograf.pdf (accessed on April 29, 2006)
25. Hines, R.N. Ontogeny of human hepatic cytochromes P450. J. Biochem. Mol. Toxicol. 2007, 21, 169-175.
26. Johnson, T.N.; Tanner, M.S.; Taylor, C.J.; Tucker, G.T. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br. J. Clin. Pharmacol. 2001, 51, 451-460.
27. Christians, U.; Strom, T.; Zhang, Y.L.; Steudel, W.; Schmitz, V.; Trump, S.; Haschke, M. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther. Drug Monit. 2006, 28, 39-44.
28. Asano, T.; Nishimoto, K.; Hayakawa, M. Increased tacrolimus trough levels in association with severe diarrhea, a case report. Transplant. Proc. 2004, 36, 2096-2097.
29. Hochleitner, B.W.; Bösmüller, C.; Nehoda, H.; Frühwirt, M.; Simma, B.; Ellemunter, H.; Steurer, W.; Hochleitner, E.O.; Königsrainer, A.; Margreiter, R. Increased tacrolimus levels during diarrhea. Transplant Int. 2001, 14, 230-233.
30. Guido, F. Calcineurin Inhibitors in Pediatric Renal Transplant Recipients. Pediatr. Drugs 2007, 9, 165-174.
31. Mahmood, B.; Daood, M.J.; Hart, C.; Hansen, T.W.; Watchko, J.F. Ontogeny of p-glycoprotein in mouse intestine, liver and kidney. J. Invest. Med. 2001, 49, 250-257.
32. Nagase, K.; Iwasaki, K.; Nozaki, K.; Noda, K. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J. Pharm. Pharmacol. 1994, 46, 113-117.
33. Venkataramanan, R.; Swaminathan, A.; Prasad, T.; Jain, A.; Zuckerman, S.; Warty, V.; McMichael, J.; Lever, J.; Burckart, G.; Starzl, T. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 1995, 29, 404-430.
34. Wijnen, R.M.; Ericzon, B.G.; Tiebosch, A.T.; Beysens, A.J.; Groth, C.G.; Kootstra, G. Toxicity of FK 506 in cynomolgus monkey: noncorrelation with FK 506 serrum levels. Transplant. Proc. 1991, 23, 3101-3104.
35. Wallemacq, P.E.; Verbeeck, R.K. Comparative clinical pharmacokinetics of tacrolimus in pediatric and adult patients. Clin Pharmacokinet. 2001, 40, 283-295.
36. Zhao, W.; Elie, V.; Roussey, G.; Brochard, K.; Niaudet, P.; Leroy, V.; Loirat, C.; Cochat, P.; Cloarec, S.; André, J.L.; Garaix, F.; Bensman, A.; Fakhoury, M.; Jacqz-Aigrain, E. Population pharmacokinetics and pharmacogenetics of tacrolimus in de nova pediatric kidney transplant recipients. Clin. Pharmacol. Therapeut. 2009, 86, 609-618.
37. Milsap, R.L.; Hill, M.R.; Szefler, S.J. Special pharmacokinetic considerations in children. In Applied Pharmacokinetics Principles of Therapeutic Drug Monitoring; Evans, W.E., Schentag, J.J., Jusko, W.J., Eds.; Applied Therapeutics Inc.,: Vancouver (WA), Canada, 1992; pp. 10-1-10-32.
38. Venkataramanan, R.; Swaminathan, A.; Prasad, T.; Jain, A.; Zuckerman, S.; Warty, V.; Lever, J.; Burckart, G.; Starzl, T. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 1995, 29, 404-430
39. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 1992, 20, 753-761.
40. Kelly, P.; kahan, B.D. Review: Metabolism of Immunosuppressant Drugs. Curr. Drug Metab. 2002, 3, 275-287.
41. Larriba, J.; Imperiali, N.; Groppa, R.; Giordani, C.; Algranatti, S.; Redal, M.A. Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients. Transplant. Proc. 2010, 42, 257-259.
42. Macphee, I.A.; Fredericks, S.; Tai, T.; Syrris, P.; Carter, N.D.; Johnston, A.; Goldberg, L.; Holt, D.W. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p450-3A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002, 74, 1486-1489.
43. Möller, A.; Iwasaki, K.; Kawamura, A.; Teramura, Y.; Shiraga, T.; Hata, T.; Schäfer, A.; Undre, N.A. The disposition of 14C-labelled tacrolimus after intravenous and oral administrationin healthy human subjects. Drug Metab. Disposition 1999, 27, 633-666.
44. Spencer, C.M.; Goa, K.L.; Gillis, J.C. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997, 54, 925-975.
45. Kamdem, L.K.; Streit, F.; Zanger, U.M.; Brockmöller, J.; Oellerich, M.; Armstrong, V.W.; Wojnowski, L. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem. 2005, 51, 1374-1381.
46. Tanaka, E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J. Clin. Pharm. Ther. 1998, 23, 247-255.
47. May, D.G.; Porter, J.; Wilkinson, G.R.; Branch, R.A. Frequency distribution of dapsone-N- Hydroxylase, a putative prove for P4503A4 activity, in a white population. Clin. Pharmacol. Ther. 1994, 55, 492-500.
48. Murry, D.J.; Crom, W.R.; Reddick, W.E.; Bhargava, R.; Evans, W.E. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab. Disposition 1995, 23, 1110-1116.
49. de Wildt, S.N.; Kearns, G.L.; Leeder, J.S.; van den Anker, J.N. Cytochrome P450 3A ontogeny and drug disposition. Clin. Pharmacokinet. 1999, 37, 485-505.
50. Przepiorka, D.; Blamble, D.; Hilsenbeck, S.; Danielson, M.; Krance, R.; Chan, K.W. Tacrolimus clearance is age-dependant within the pediatric population. Bone Marrow Transplant. 2000, 26, 601-605.
51. Montini, G.; Ujka, F.; Varagnolo, C.; Ghio, L.; Ginevri, F.; Murer, L.; Thafam, B.S.; Carasi, C.; Zacchello, G.; Plebani, M. The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. Pediatr. Nephrol. 2006, 21, 719-724.